Back to search
FDAFDA · Food and drugs·Recall number D-1253-2020

Nizatidine Oral Solution, 15 mg/mL (75 mg/5mL) USP 480 mL bottles, Rx Only Distributed by: Gemini Laboratories, LLC Bridgewater, NJ 08807 NDC 60846-301-15

Published May 6, 2020 · Recall initiated: April 15, 2020

Summary

FDA records drug Class II recall D-1253-2020, published May 6, 2020 and initiated April 15, 2020. Recalling firm: Amneal Pharmaceuticals of New York, LLC; Status: Terminated; Reported quantity: 11258 bottles; Lot: 06598004A 04/2020 06599001A 12/2020 06599002A 12/2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.

What to do

Voluntary: Firm initiated · Press Release

Get an email if NIZATIDINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NIZATIDINE
Manufacturer
Amneal Pharmaceuticals of New York, LLC
Distributor
Nationwide
Lot
06598004A 04/2020 06599001A 12/2020 06599002A 12/2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Nizatidine Oral Solution, 15 mg/mL (75 mg/5mL) USP 480 mL bottles, Rx Only Distributed by: Gemini Laboratories, LLC Bridgewater, NJ 08807 NDC 60846-301-15 recalled?

Yes. FDA published recall D-1253-2020 on May 6, 2020. Reported hazard: CGMP Deviations: potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NIZATIDINE.